Endothelial dysfunction is the main pathogenic event of diabetes-related vascular disease at the earliest stage of vascular injury
Comparing Retatrutide to the Landscape of Peptide Medications Retatrutides introduction prompts a comparison with other weight loss peptides in the market
GLP-1 Success A better GLP-1 journey starts here Mike -135 LBS *Eligible patients lost an average of 21% of their body weight (-48 lbs) in a 72-week clinical trial evaluating 15 mg tirzepatide, when paired with diet and exercise
By combining peripheral effects (slower gastric emptying, metabolic adjustments) with central nervous system actions (reduced hunger and altered food reward), GLP-1 RAs produce sustained reductions in caloric intake and clinically meaningful weight loss
More emphasis needs to be put on supporting those who actually are running trials trying to figure out this information or forcing large phase 3 trials (who are collecting this data) to actually report on the outcomes, so we can provide evidence based DIET & EXERCISE recommendations
The Key Difference: Receptor Activity The most significant distinction between Retatrutide and Semaglutide lies in the number of receptors they target
